This study validates and expands on our previous work that assessed three-dimensional (3D) nuclear telomere profiling in buccal cells of Alzheimer's disease (AD) patients and non-AD controls (Mathur et al., J Alzheimers Dis 39, 35-48, 2014). While the previous study used age- and gender-matched caregiver controls, the current study consented a new cohort of 44 age- and gender-matched healthy no...

1. Porteri C, Galluzzi S, Geroldi C, Frisoni GB. Diagnosis disclosure of prodromal Alzheimer disease – ethical analysis of two cases. Can J Neurol Sci. 2010; 37: 67-75. 2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revisiting of the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6: 734-46. 3. Gauthi...

Numerous reports over the years have described neuroinflammatory events and vascular changes in neurodegenerative diseases such as Alzheimers disease (AD) and Dementia with Lewy bodies (DLB). Interestingly, recent reports from other research areas suggest that inflammatory and vascular processes are influenced by gender. These findings are intriguing from the perspective that women show a highe...

Objective: Mild cognitive impairment (MCI) refers to the clinical condition between normal aging and Alzheimer’s disease (AD). Heterogeneity in this entity has also been recognized, and an accelerated rate of progression to AD was documented in some individuals diagnosed with MCI. It is important for the early detection of and intervention for AD to determine the clinical subtype of MCI with a ...

Alzheimer’s disease (AD) and Parkinson’s disease (PD) pose significant challenges for successful development of new therapies, with anextremely high drug trial failure rate and yet no approved disease modifying drugs available. Given the magnitude of the challenges, it has become clear that larger collaborations and multi-partner joint efforts, pooling resources and expertise,are required for t...

Fluorodeoxyglucose (FDG) positron emission tomography (PET) measures the decline in the regional cerebral metabolic rate for glucose, offering a reliable metabolic biomarker even on presymptomatic Alzheimer's disease (AD) patients. PET scans provide functional information that is unique and unavailable using other types of imaging. However, the computational efficacy of FDG-PET data alone, for ...